Drugs / ARCT-2138
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06125691 | Jan → Aug 2024 | influenza | Arcturus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARCT-2138 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06125691 ↗ |
| Modality | Small activating RNA (saRNA) | “Self-Amplifying RNA seasonal Influenza vaccine” NCT06125691 ↗ |
| Route | Intramuscular | “one 0.5 mL intramuscular (IM) dose into the deltoid muscle.” NCT06125691 ↗ |